Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials

Archives of Dermatology

Volumn 148, Issue 4, 2012, Pages 463-470

  Garcia Doval, Ignacio ^a   Carretero, Gregorio ^b   Vanaclocha, Francisco ^c   Ferrandiz, Carlos ^d   Daudén, Esteban ^e   Sánchez Carazo, Jose Luis ^f   Alsina, Mercé ^g   Herrera Ceballos, Enrique ^h   Gómez García, Francisco José ⁱ   Ferrán, Marta ^j   López Estebaranz, Jose Luis ^k   Hernanz, Jose Manuel ^l   Belinchón Romero, Isabel ^m   Vilar Alejo, Jaime ^b   Rivera, Raquel ^c   Carrascosa, Jose Manuel ^d   Carazo, Cristina ^e  

^a HOSPITAL MONTECELO   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁱ Hospital Universitario Reina Sofia Cordoba   (Argentina)

^j HOSPITAL DEL MAR   (Spain)

^k HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^l HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ADULT; AGED; AGING; ARTICLE; CHRONIC HEPATITIS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SKIN CANCER; SYSTEMIC THERAPY; ULTRAVIOLET B RADIATION;

ADULT; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PSORIASIS; PUVA THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SPAIN;

EID: 84859992591     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.2768     Document Type: Article

References (18)

1. Ferrándiz C, Bordas X, García-Patos V, Puig S, Pujol R, Smandía A. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol. 2001;15(1):20-23. (Pubitemid 32842768)
2. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3(2): 121-128. (Pubitemid 38832741)
3. Ferrándiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? the biologics: facts and controversies. Clin Dermatol. 2010;28(1):81-87.
4. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: metaanalysis of randomized controlled trials. Br J Dermatol. 2008;159(3):513-526.
5. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011; 2(2):CD008794.
6. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(2):274-285. (Pubitemid 352009861)
7. Wang D, Bakhai A. Patient Selection: Clinical Trials: A Practical Guide to Design, Analysis, and Reporting. Chicago, IL: Remedica; 2006:47-54.
8. Nijsten T, Spuls PI, Naldi L, Stern RS. The misperception that clinical trial data reflect long-term drug safety: lessons learned from efalizumab's withdrawal. Arch Dermatol. 2009;145(9):1037-1039.
9. Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology. 2006;213(4):327-330. (Pubitemid 44837021)
10. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor α agents in rheumatoid arthritis. Arthritis Rheum. 2003; 48(2):313-318. (Pubitemid 36277997)
11. Kievit W, Fransen J, Oerlemans AJ, et al. The efficacy of anti-TNF in rheumatoid arthritis: a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66(11):1473-1478. (Pubitemid 350032655)
12. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54(11):3399-3407. (Pubitemid 44737150)
13. Rivera R, García-Doval I, Carretero G, et al; Miembros del grupo BIOBADADERM. BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report. Actas Dermosifiliogr. 2011;102 (2):132-141.
14. International Conference on Harmonisation: clinical safety data management: definitions and standards for expedited reporting: E2A. http://www.ich.org/fileadmin /Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E2B/Step4/E2B-R2 --Guideline.pdf. Accessed February 12, 2011.
15. BIOBADADERM. BIOBADADERM table of drug half-lives and lag windows for attribution of adverse events. https://biobadaser.ser.es/biobadaderm/cgi-bin/ upload /documentacion.aspx. Accessed March 29, 2011.
16. Lecluse LL, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for psoriasis and the European "Psonet" initiative. Dermatology. 2009; 218(4):347-356.
17. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol. 1988;91(3):197-201.
18. Marshall SW. Power for tests of interaction: effect of raising the type I error rate. Epidemiol Perspect Innov. 2007;4:4. doi:10.1186/1742-5573-4-4.